Presentation is loading. Please wait.

Presentation is loading. Please wait.

The Presence of Mutations in Epidermal Growth Factor Receptor Gene Is Not a Prognostic Factor for Long-Term Outcome after Surgical Resection of Non–Small-Cell.

Published byIngrid Arntzen Modified over 5 years ago

Similar presentations

Presentation on theme: "The Presence of Mutations in Epidermal Growth Factor Receptor Gene Is Not a Prognostic Factor for Long-Term Outcome after Surgical Resection of Non–Small-Cell."— Presentation transcript:

1 The Presence of Mutations in Epidermal Growth Factor Receptor Gene Is Not a Prognostic Factor for Long-Term Outcome after Surgical Resection of Non–Small-Cell Lung Cancer  Young Tae Kim, MD, PhD, Yong Won Seong, MD, Yoo Jin Jung, MS, Yoon Kyung Jeon, MD, PhD, In Kyu Park, MD, PhD, Chang Hyun Kang, MD, PhD, Joo Hyun Kim, MD, PhD  Journal of Thoracic Oncology  Volume 8, Issue 2, Pages (February 2013) DOI: /JTO.0b013e318277a3bb Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Comparison of survival curve after curative resection of NSCLC according to the presence of EGFR mutations (Kaplan–Meier's survival curve with log-rank test). NSCLC, non–small-cell lung cancer; EGFR, epidermal growth factor receptor. Journal of Thoracic Oncology 2013 8, DOI: ( /JTO.0b013e318277a3bb) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Comparison of survival curve after recurrence according to the presence of EGFR mutations (A), Kaplan–Meier's survival curve with log-rank test and smoking status (B), Cox's proportional hazard model. EGFR, epidermal growth factor receptor. Journal of Thoracic Oncology 2013 8, DOI: ( /JTO.0b013e318277a3bb) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 Comparison of survival curve after recurrence according to the presence of EGFR mutations and palliative treatment modalities (Kaplan–Meier's survival curve with log-rank test) (A), wild-type EGFR, (B), mutated EGFR.EGFR, epidermal growth factor receptor. Journal of Thoracic Oncology 2013 8, DOI: ( /JTO.0b013e318277a3bb) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

5 FIGURE 4 Comparison of disease-free survival (A), and freedom from recurrence (B), according to the presence of EGFR mutations (Kaplan–Meier's survival curve with log-rank test). EGFR, epidermal growth factor receptor. Journal of Thoracic Oncology 2013 8, DOI: ( /JTO.0b013e318277a3bb) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "The Presence of Mutations in Epidermal Growth Factor Receptor Gene Is Not a Prognostic Factor for Long-Term Outcome after Surgical Resection of Non–Small-Cell."

Similar presentations

Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 

Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 
Sukki Cho, MD, Kyung-Min Ryu, MD, Yoon-Jin Hwang, MD, Eung Bae Lee, MD 

Sukki Cho, MD, Kyung-Min Ryu, MD, Yoon-Jin Hwang, MD, Eung Bae Lee, MD 
Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma  Kazuya Takamochi, MD, Shiaki Oh, MD,

Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma  Kazuya Takamochi, MD, Shiaki Oh, MD,
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.
Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,

Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,
Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,
Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer?: Implications for Selection.

Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer?: Implications for Selection.
Quantification of emphysema with preoperative computed tomography has stronger association with pulmonary complications than pulmonary function test results.

Quantification of emphysema with preoperative computed tomography has stronger association with pulmonary complications than pulmonary function test results.
A novel detection method of non–small cell lung cancer using multiplexed bead-based serum biomarker profiling  Hyun Joo Lee, MD, PhD, Young Tae Kim, MD,

A novel detection method of non–small cell lung cancer using multiplexed bead-based serum biomarker profiling  Hyun Joo Lee, MD, PhD, Young Tae Kim, MD,
Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer?: Implications for Selection.

Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer?: Implications for Selection.
Prognostic Significance of PD-L1 in Patients with Non–Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases  Jong-Mu Sun, MD, Wei.

Prognostic Significance of PD-L1 in Patients with Non–Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases  Jong-Mu Sun, MD, Wei.
Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 
The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR- Mutant Non–Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors 

The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR- Mutant Non–Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors 
Tumor Necrosis as a Prognostic Factor for Stage IA Non-Small Cell Lung Cancer  Seong Yong Park, MD, Hyun-Sung Lee, MD, PhD, Hee-Jin Jang, MD, Geon Kook.

Tumor Necrosis as a Prognostic Factor for Stage IA Non-Small Cell Lung Cancer  Seong Yong Park, MD, Hyun-Sung Lee, MD, PhD, Hee-Jin Jang, MD, Geon Kook.
The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review  Swati Kulkarni, MD, Emily T. Vella,

The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review  Swati Kulkarni, MD, Emily T. Vella,
Incidence of Brain Metastasis at the Initial Diagnosis of Lung Squamous Cell Carcinoma on the Basis of Stage, Excluding Brain Metastasis  Hyun Lee, MD,

Incidence of Brain Metastasis at the Initial Diagnosis of Lung Squamous Cell Carcinoma on the Basis of Stage, Excluding Brain Metastasis  Hyun Lee, MD,
Can Aberrant Promoter Hypermethylation of CpG Islands Predict the Clinical Outcome of Non-Small Cell Lung Cancer After Curative Resection?  Young Tae.

Can Aberrant Promoter Hypermethylation of CpG Islands Predict the Clinical Outcome of Non-Small Cell Lung Cancer After Curative Resection?  Young Tae.
The prognostic impact of microRNA sequence polymorphisms on the recurrence of patients with completely resected non–small cell lung cancer  Kyong-Ah Yoon,

The prognostic impact of microRNA sequence polymorphisms on the recurrence of patients with completely resected non–small cell lung cancer  Kyong-Ah Yoon,
First-Line Gefitinib Treatment for Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status  Young Joo Lee, MD, Heung Tae Kim, MD,

First-Line Gefitinib Treatment for Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status  Young Joo Lee, MD, Heung Tae Kim, MD,
Tetsuya Mitsudomi, MD, Hirohito Tada, MD  Journal of Thoracic Oncology 

Tetsuya Mitsudomi, MD, Hirohito Tada, MD  Journal of Thoracic Oncology 

Similar presentations

Ads by Google